alendronate has been researched along with Bone Stress Reaction in 39 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Several recent medical articles have described multiple cases of unusual low-impact subtrochanteric stress fractures or completed fractures of the femur in patients who have been on the bisphosphonate alendronate for several years for osteoporosis or osteopenia." | 7.75 | Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. ( Schneider, JP, 2009) |
| " The current treatment for preventing and treating osteoporotic fractures is the use of antiresorptive drugs such as bisphosphonates (BPs) and denosumab, but unfortunately, their long-term use, especially with alendronate and ibandronate, has been associated with increased risk of atypical femoral fractures (AFFs); femoral diaphyseal fractures distal to the lesser trochanter but proximal to the supracondylar flare." | 5.22 | Effects of bisphosphonates on appendicular fracture repair in rodents. ( Hadjiargyrou, M, 2022) |
| "One of the patients was treated with alendronate therapy in concern of her risk factors for osteoporosis (her previous a hysterectomy with bilateral oophorectomy) with unsubstantiated evidence of her pretreatment, bone-mineral-density measurements (BMD), for a 10-year prior episode of left prodromal thigh pain and an insufficiency fracture at 8 days post experiencing the pain." | 3.77 | Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases. ( Angthong, C; Angthong, W, 2011) |
| "Several recent medical articles have described multiple cases of unusual low-impact subtrochanteric stress fractures or completed fractures of the femur in patients who have been on the bisphosphonate alendronate for several years for osteoporosis or osteopenia." | 3.75 | Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. ( Schneider, JP, 2009) |
| " The recommendations for the management and care of patients who are on long-term use of alendronate (bisphosphonates) are summarized." | 2.46 | Risk of atypical femoral fracture with long-term use of alendronate (bisphosphonates) : a systemic review of literature. ( Agarwal, G; Agarwal, PK; Agarwal, S; Bansal, A; Gupta, P, 2010) |
| "Alendronate treatment was ceased." | 1.46 | Surgical treatment of bilateral femoral stress fractures related with long-term alendronate therapy. ( Ataoğlu, MB; Çetinkaya, M; Kanatlı, U; Özer, M; Topçu, HN, 2017) |
| " During the last decade, the occurrence of atypical fractures, mostly subtrochanteric and diaphyseal femoral fractures, has been acknowledged in patients with long-term use of bisphosphonates." | 1.43 | Bilateral distal fibula fractures in a woman on long-term bisphosphonate therapy. ( Audet, MC; Bédard, M; Michou, L; Murray, JC, 2016) |
| " We assumed that both of the fractures were associated with the long-term use of alendronate." | 1.43 | Localized cortical thickening of the femoral diaphysis captured on an X-ray before alendronate therapy in two cases of atypical femoral fracture. ( Iizuka, H; Iizuka, Y; Omodaka, T; Takagishi, K; Takechi, R, 2016) |
| "We report a case of bilateral ulna stress fractures following bilateral femoral fractures associated with long-term bisphosphonate use." | 1.39 | Bilateral ulna fractures associated with bisphosphonate therapy. ( Ang, BF; Howe, TS; Koh, JS; Ng, AC, 2013) |
| "Bisphosphonate-associated stress fractures and completed fractures are unique, possessing subtle characteristic radiographic features." | 1.38 | Femoral stress fractures associated with long-term bisphosphonate treatment. ( Carter, CJ; Emory, CL; Ward, WG; Wilson, SC, 2012) |
| " Long-term use of bisphosphonates may lead to low-energy femoral subtrochanteric or shaft fractures in a very few patients." | 1.38 | Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report. ( Chen, CH; Chen, JC; Cheng, YM; Fu, YC; Hsieh, CH; Huang, HT; Huang, PJ; Kang, L; Lin, SY, 2012) |
| " Concerns have been raised about potential oversuppression of bone turnover and the development of atypical skeletal fragility associated with long-term use of bisphosphonates." | 1.36 | Atypical insufficiency fracture of the tibia associated with long-term bisphosphonate therapy. ( Breglia, MD; Carter, JD, 2010) |
| "Stress fractures were induced in the ulnae of female adult rats." | 1.36 | Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair. ( Li, J; Li, S; Martin, JR; Sloan, AV, 2010) |
| "Subtrochanteric insufficiency fractures in post-menopausal patients have not been commonly reported in the literature." | 1.35 | An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? ( Goh, SK; Howe, TS; Koh, JS; Kwek, EB; Png, MA, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (20.51) | 29.6817 |
| 2010's | 29 (74.36) | 24.3611 |
| 2020's | 2 (5.13) | 2.80 |
| Authors | Studies |
|---|---|
| Hadjiargyrou, M | 1 |
| Gharanizadeh, K | 1 |
| Ravanbod, H | 1 |
| Aminian, A | 1 |
| Hatami, S | 1 |
| Chaleshtori, AS | 1 |
| Kazerani, S | 1 |
| Drampalos, E | 1 |
| Skarpas, G | 1 |
| Barbounakis, N | 1 |
| Michos, I | 1 |
| Ward, JP | 1 |
| Strauss, EJ | 1 |
| Tejwani, NC | 1 |
| Chiang, GS | 1 |
| Grace, CS | 1 |
| Koh, KW | 1 |
| Kelvin, KW | 1 |
| Chong, TW | 1 |
| Wei, CT | 1 |
| Tan, BY | 1 |
| Yeow, TB | 1 |
| Skoglund, K | 1 |
| Hjortdal, O | 1 |
| Murray, JC | 1 |
| Audet, MC | 1 |
| Bédard, M | 1 |
| Michou, L | 1 |
| Iizuka, Y | 1 |
| Takechi, R | 1 |
| Iizuka, H | 1 |
| Omodaka, T | 1 |
| Takagishi, K | 1 |
| Kanatlı, U | 1 |
| Ataoğlu, MB | 1 |
| Özer, M | 1 |
| Topçu, HN | 1 |
| Çetinkaya, M | 1 |
| Schneider, JP | 1 |
| Edwards, MH | 1 |
| McCrae, FC | 1 |
| Young-Min, SA | 1 |
| Paccou, J | 1 |
| Viget, N | 1 |
| Legrout-Gérot, I | 1 |
| Yazdanpanah, Y | 1 |
| Cortet, B | 1 |
| Cermak, K | 1 |
| Shumelinsky, F | 1 |
| Alexiou, J | 1 |
| Gebhart, MJ | 1 |
| Breglia, MD | 1 |
| Carter, JD | 1 |
| Das De, S | 3 |
| Setiobudi, T | 2 |
| Shen, L | 1 |
| Singh, S | 1 |
| Singh, V | 1 |
| Joshi, A | 1 |
| O'Neal, JM | 1 |
| Diab, T | 1 |
| Allen, MR | 1 |
| Vidakovic, B | 1 |
| Burr, DB | 1 |
| Guldberg, RE | 1 |
| Aspenberg, P | 1 |
| Schilcher, J | 1 |
| Fahlgren, A | 1 |
| Sloan, AV | 1 |
| Martin, JR | 1 |
| Li, S | 1 |
| Li, J | 1 |
| Agarwal, S | 2 |
| Gupta, P | 1 |
| Agarwal, PK | 1 |
| Agarwal, G | 1 |
| Bansal, A | 1 |
| Osugi, K | 1 |
| Miwa, S | 1 |
| Marukawa, S | 1 |
| Marukawa, K | 1 |
| Kawaguchi, Y | 1 |
| Nakato, S | 1 |
| Gomberg, SJ | 1 |
| Wustrack, RL | 1 |
| Napoli, N | 1 |
| Arnaud, CD | 1 |
| Black, DM | 1 |
| Wang, K | 1 |
| Moaveni, A | 1 |
| Dowrick, A | 1 |
| Liew, S | 1 |
| Puah, KL | 1 |
| Tan, MH | 1 |
| Jamal, SA | 1 |
| Dion, N | 1 |
| Ste-Marie, LG | 1 |
| Bjørgul, K | 1 |
| Reigstad, A | 1 |
| Ward, WG | 1 |
| Carter, CJ | 1 |
| Wilson, SC | 1 |
| Emory, CL | 1 |
| Curtin, BM | 1 |
| Fehring, TK | 1 |
| Lim, CT | 1 |
| Angthong, C | 1 |
| Angthong, W | 1 |
| Seraphim, A | 1 |
| Al-Hadithy, N | 1 |
| Mordecai, SC | 1 |
| Al-Nammari, S | 1 |
| Ang, BF | 1 |
| Koh, JS | 2 |
| Ng, AC | 1 |
| Howe, TS | 2 |
| Huang, HT | 1 |
| Kang, L | 1 |
| Huang, PJ | 1 |
| Fu, YC | 1 |
| Lin, SY | 1 |
| Hsieh, CH | 1 |
| Chen, JC | 1 |
| Cheng, YM | 1 |
| Chen, CH | 1 |
| Barrett, JG | 1 |
| Sample, SJ | 1 |
| McCarthy, J | 1 |
| Kalscheur, VL | 1 |
| Muir, P | 1 |
| Prokuski, L | 1 |
| Kwek, EB | 1 |
| Goh, SK | 1 |
| Png, MA | 1 |
| Kushida, K | 1 |
| Iba, K | 1 |
| Kishimoto, H | 1 |
| Inaba, M | 1 |
9 reviews available for alendronate and Bone Stress Reaction
| Article | Year |
|---|---|
Effects of bisphosphonates on appendicular fracture repair in rodents.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Denosumab; Diphosphonates; | 2022 |
Alendronate-related femoral diaphysis fracture--what should be done to predict and prevent subsequent fracture of the contralateral side?
Topics: Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Fractures, Stress; Humans; | 2010 |
Bone loss in patients with HIV infection.
Topics: Alendronate; Anti-Retroviral Agents; Bone Density; Bone Density Conservation Agents; Bone Resorption | 2009 |
Risk of atypical femoral fracture with long-term use of alendronate (bisphosphonates) : a systemic review of literature.
Topics: Alendronate; Bone Density Conservation Agents; Femoral Fractures; Fractures, Stress; Humans | 2010 |
Do bisphosphonates cause femoral insufficiency fractures?
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Femoral Fractures; Fractures | 2012 |
[Bone densitometry: its clinical application and current status].
Topics: Alendronate; Bone Density; Clinical Trials as Topic; Densitometry; Fractures, Stress; Humans; Osteop | 2002 |
[Treatment of male osteoporosis].
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Calcium; Fractures, Stress | 2002 |
[Bisphosphonates: pharmacology and use in the treatment of osteoporosis].
Topics: Alendronate; Bone Density; Bone Remodeling; Clinical Trials as Topic; Diphosphonates; Etidronic Acid | 2002 |
[Alendronate in the treatment of osteoporosis].
Topics: Alendronate; Bone Density; Bone Resorption; Clinical Trials as Topic; Femoral Neck Fractures; Fractu | 2002 |
30 other studies available for alendronate and Bone Stress Reaction
| Article | Year |
|---|---|
Acetabular and sacral insufficiency fractures in a patient with a long-term history of Alendronate consumption; a case report.
Topics: Acetabulum; Alendronate; Diphosphonates; Female; Fractures, Bone; Fractures, Stress; Humans; Middle | 2023 |
Atypical femoral fractures bilaterally in a patient receiving denosumab.
Topics: Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; D | 2014 |
Injury to the superior gluteal artery during intramedullary fixation of an atypical subtrochanteric stress fracture - a case report.
Topics: Alendronate; Arteries; Blood Transfusion; Bone Density Conservation Agents; Bone Nails; Buttocks; Fe | 2013 |
Stress fracture of the ulna associated with bisphosphonate therapy and use of walking aid.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Female; Fractures, Stress; Humans; Magnetic Res | 2014 |
Femoral fracture and temporomandibular joint destruction following the use of bisphosphonates.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Female; Fract | 2015 |
Bilateral distal fibula fractures in a woman on long-term bisphosphonate therapy.
Topics: Alendronate; Ankle Injuries; Bone Density Conservation Agents; Diphosphonates; Female; Fibula; Fract | 2016 |
Localized cortical thickening of the femoral diaphysis captured on an X-ray before alendronate therapy in two cases of atypical femoral fracture.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diagnosis, Differential; Dia | 2016 |
Surgical treatment of bilateral femoral stress fractures related with long-term alendronate therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcium; Female; Femoral Fractures; Fractures, | 2017 |
Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Resorption; Drug Administration Schedule; | 2009 |
Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Nails; Female; Femoral Fractures; Fracture | 2010 |
Atypical insufficiency fracture of the tibia associated with long-term bisphosphonate therapy.
Topics: Adrenal Cortex Hormones; Alendronate; Antirheumatic Agents; Arthritis, Rheumatoid; Diphosphonates; F | 2010 |
A rational approach to management of alendronate-related subtrochanteric fractures.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density; Bone Density Conservation A | 2010 |
Comment on Xue et al.: Alendronate treatment improves bone-pedicle screw interface fixation in posterior lateral spine fusion: an experimental study in a porcine model.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Remodeling; Bone Screws; Disease Models | 2010 |
One year of alendronate treatment lowers microstructural stresses associated with trabecular microdamage initiation.
Topics: Alendronate; Animals; Bone and Bones; Calcification, Physiologic; Dogs; Female; Finite Element Analy | 2010 |
Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment. Frozen bone with remodelling at the crack.
Topics: Alendronate; Bone Density Conservation Agents; Bone Nails; Bone Resorption; Etidronic Acid; Female; | 2010 |
Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Remodeling; Diphosphonates; Female | 2010 |
Diaphyseal femoral fatigue fracture associated with bisphosphonate therapy - 3 more cases.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Femoral Fractures; Frac | 2011 |
Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Female; Femoral Fractures; Fra | 2011 |
Alendronate-associated femoral insufficiency fractures and femoral stress reactions.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Nails; Female; Femoral | 2011 |
Bisphosphonate-associated atypical fracture of the femur: Spontaneous healing with drug holiday and re-appearance after resumed drug therapy with bilateral simultaneous displaced fractures--a case report.
Topics: Alendronate; Bone Density Conservation Agents; Bone Plates; Female; Femoral Fractures; Follow-Up Stu | 2011 |
Atypical femoral fractures and bone turnover.
Topics: Alendronate; Bone Remodeling; Diphosphonates; Female; Femoral Fractures; Femur; Fractures, Stress; H | 2011 |
Atypical fracture of the ulna associated with alendronate use.
Topics: Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Fracture Healing; Fracture | 2011 |
Femoral stress fractures associated with long-term bisphosphonate treatment.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Female; Femoral Fractures; Fractures, Stress; | 2012 |
Bisphosphonate fractures as a cause of painful total hip arthroplasty.
Topics: Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Arthroplasty, Replacement, Knee; Bone D | 2011 |
Femoral canal obliteration secondary to prolonged alendronate use: a case report.
Topics: Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Fractur | 2012 |
Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; F | 2011 |
Bilateral ulna fractures associated with bisphosphonate therapy.
Topics: Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Female; Fractures, Stress; Humans; | 2013 |
Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report.
Topics: Alendronate; Bone Density Conservation Agents; Female; Femoral Fractures; Fractures, Stress; Humans; | 2012 |
Effect of short-term treatment with alendronate on ulnar bone adaptation to cyclic fatigue loading in rats.
Topics: Adaptation, Physiological; Alendronate; Animals; Bone Density; Bone Remodeling; Fractures, Stress; M | 2007 |
An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Femora | 2008 |